[go: up one dir, main page]

UY33526A - Nuevas aminopirazoloquinazolinas - Google Patents

Nuevas aminopirazoloquinazolinas

Info

Publication number
UY33526A
UY33526A UY0001033526A UY33526A UY33526A UY 33526 A UY33526 A UY 33526A UY 0001033526 A UY0001033526 A UY 0001033526A UY 33526 A UY33526 A UY 33526A UY 33526 A UY33526 A UY 33526A
Authority
UY
Uruguay
Prior art keywords
aminopirazoloquinazolinas
new
compounds
medicines
radicals
Prior art date
Application number
UY0001033526A
Other languages
English (en)
Inventor
Treu Matthias
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43037625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33526(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY33526A publication Critical patent/UY33526A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención comprende compuestos de la fórmula general (I) en donde los radicales R1 hasta R3 y X están definidos como en la reivindicación 1, que son apropiados para el tratamiento de enfermedades que se caracterizan por una proliferación celular excesiva o anómala, a preparaciones farmacéuticas que contienen tales compuestos y a su emp leo como medicamentos.
UY0001033526A 2010-07-23 2011-07-21 Nuevas aminopirazoloquinazolinas UY33526A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10170683 2010-07-23

Publications (1)

Publication Number Publication Date
UY33526A true UY33526A (es) 2012-02-29

Family

ID=43037625

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033526A UY33526A (es) 2010-07-23 2011-07-21 Nuevas aminopirazoloquinazolinas

Country Status (23)

Country Link
US (1) US8735386B2 (es)
EP (1) EP2595987B1 (es)
JP (1) JP5991974B2 (es)
KR (1) KR20130132394A (es)
CN (1) CN103097388A (es)
AP (1) AP2012006640A0 (es)
AR (1) AR082850A1 (es)
AU (1) AU2011281504A1 (es)
BR (1) BR112013000107A2 (es)
CA (1) CA2803467A1 (es)
CL (1) CL2012003745A1 (es)
CO (1) CO6670575A2 (es)
EA (1) EA201201661A1 (es)
EC (1) ECSP13012448A (es)
GE (1) GEP20156289B (es)
MA (1) MA34389B1 (es)
MX (1) MX2013000821A (es)
PE (1) PE20131143A1 (es)
PH (1) PH12013500152A1 (es)
SG (1) SG187548A1 (es)
TW (1) TW201217380A (es)
UY (1) UY33526A (es)
WO (1) WO2012010704A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2807166B1 (en) 2012-01-23 2016-04-06 Boehringer Ingelheim International GmbH 5,8-dihydro-6h-pyrazolo[3,4-h]quinazolines as igf-1r/ir inhibitors
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
SG10201809189UA (en) * 2013-11-15 2018-11-29 Oncoceutics Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use
SMT202000696T1 (it) 2015-01-30 2021-01-05 Oncoceutics Inc 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9- esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-one e suoi sali e loro uso in terapia
EP3294742B1 (en) * 2015-05-13 2020-01-08 Boehringer Ingelheim International GmbH New (5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h)quinazolin-2-yl)-(1h-pyrazol-5-yl)-amines and theri derivatives as igf-1r/1r inhibitors.
JP6905069B2 (ja) * 2016-11-11 2021-07-21 上海海雁醫藥科技有限公司 ピリジルアミノ置換へテロ三環式化合物並びにその製造方法及び医薬用途
DK3632904T3 (da) * 2017-05-26 2022-07-25 Jiangsu Atom Bioscience And Pharmaceutical Co Ltd URAT1-inhibitorer til at fremme urinsyreudskillelse
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
JP2021521282A (ja) * 2018-04-24 2021-08-26 上海海雁医薬科技有限公司Ｓｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． Ｃｄｋ４／６阻害剤、その薬学的に許容可能な塩と結晶多形体、及びその応用
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
EP3917514A4 (en) * 2019-01-30 2023-02-22 Yale University COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF FIBROSIS
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
BR112021016960A2 (pt) * 2019-03-07 2021-11-23 BioNTech SE Processo para a preparação de uma imidazoquinolina substituída
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
JP2022531094A (ja) * 2019-04-19 2022-07-06 ファウント バイオ， インコーポレイテッド 皮膚内への活性剤の送達および保持
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
EP4013750A1 (en) 2019-08-14 2022-06-22 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CA3157681A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
MX2022015410A (es) 2020-06-05 2023-03-13 Kinnate Biopharma Inc Inhibidores de las cinasas receptoras del factor de crecimiento de fibroblastos.
CN111960974A (zh) * 2020-08-28 2020-11-20 山东潍坊润丰化工股份有限公司 一种烯草酮中间体的合成方法
JP7545622B2 (ja) * 2021-02-08 2024-09-05 江蘇星盛新輝医薬有限公司 ５，６－ジドヒロチエノ［３，４－ｈ］キナゾリン系化合物
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1118460C (zh) * 1995-10-02 2003-08-20 弗·哈夫曼-拉罗切有限公司 作为5HTzc-受体拮抗剂的嘧啶衍生物
RS20050944A (en) 2003-05-22 2008-06-05 Nerviano Medical Sciences S.R.L., Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法

Also Published As

Publication number Publication date
AU2011281504A1 (en) 2013-01-10
EA201201661A1 (ru) 2013-07-30
EP2595987A1 (en) 2013-05-29
US20120238542A1 (en) 2012-09-20
JP5991974B2 (ja) 2016-09-14
SG187548A1 (en) 2013-03-28
AP2012006640A0 (en) 2012-12-31
GEP20156289B (en) 2015-05-25
PE20131143A1 (es) 2013-10-23
EP2595987B1 (en) 2018-04-18
TW201217380A (en) 2012-05-01
BR112013000107A2 (pt) 2016-05-17
CA2803467A1 (en) 2012-01-26
US8735386B2 (en) 2014-05-27
MX2013000821A (es) 2013-05-30
CN103097388A (zh) 2013-05-08
PH12013500152A1 (en) 2013-02-18
AR082850A1 (es) 2013-01-16
CL2012003745A1 (es) 2013-05-31
JP2013532652A (ja) 2013-08-19
ECSP13012448A (es) 2013-03-28
CO6670575A2 (es) 2013-05-15
KR20130132394A (ko) 2013-12-04
MA34389B1 (fr) 2013-07-03
WO2012010704A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
UY33526A (es) Nuevas aminopirazoloquinazolinas
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
CY1119387T1 (el) Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
ECSP11011558A (es) Nuevos compuestos químicos.
MA33939B1 (fr) 5-alcynyl-pyrimidines
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
UY32916A (es) Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones
UY33890A (es) Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa
BR112012029647A2 (pt) novos derivados de pirimidinas
UY31198A1 (es) Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones.
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
UY33349A (es) Nuevos compuestos de quinoxalina, quinolina y quinazolina, composiciones farmacéuticas que los contienen y uso de los mismos
ECSP14013215A (es) Compuestos novedosos
CO6331434A2 (es) Nuevos compuestos
BR112014026817A2 (pt) derivados do pantotenato para o tratamento de transtornos neurológicos
CO6460762A2 (es) 5-alquinil-piridinas
ECSP12012110A (es) 5-alquinil-pirimidinas
ECSP11011464A (es) Tia-triaza-ciclopentazulenos
TN2013000012A1 (en) New aminopyrazoloquinazolines
UY33816A (es) ?nuevas triazolilfenil sulfonamidas como inhibidores de serina/treonina cinasa?.
ECSP12012115A (es) 5-alquinil-pirimidinas
UA107920C2 (en) Substituted pyrimidine for the treatment of diseases such as cancer

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200813